GCC And UAE Diabetes Devices Market Size, Share & Trends Analysis Report By Services (Pharma, Drugs & Supplies), By Distribution Channel (Hospital Pharmacies,) By End-use, By Country, And Segment Forecasts, 2025 - 2030

GCC And UAE Diabetes Devices Market Growth & Trends

The GCC and UAE diabetes devices market size is estimated to reach USD 4.73 billion by 2030, registering to grow at a CAGR of 7.3% from 2025 to 2030 according to a new report by Grand View Research, Inc. Factors such as the increasing prevalence of diabetes, rapid technological advancements, and increasing awareness related to diabetes preventive care are all augmenting the market growth during the forecast period. For instance, in December 2021, Sanofi signed a contract with the Dasman Diabetes Institute and Research Center (DDI), a research institute & diabetes treatment center in Kuwait, to enhance diabetes control and prevention in the country.

Diabetes is a rapidly growing disease. Some of the highest diabetes prevalence rates in the world are found in the countries of the Gulf Cooperation Council. The increase in unhealthy living continues to lead to a more unhealthy population in the region. According to International Diabetes Federation, in 2021, there were about 0.8 million patients suffering from diabetes in Kuwait, and this number is expected to increase to 1.0 million by 2045.

Over the past few decades, diabetes-related research activity has been observed to be low in this region. However, an increase in research funding and collaborations between local & international researchers and institutes are expected to boost segment growth. For instance, in January 2022, the Saudi Health Council signed a memorandum of understanding with Sanofi, a French healthcare corporation, to collaborate on diabetes research and development.

The key market players are implementing a variety of strategies, including mergers and acquisitions, partnerships, collaborations, and expansions. For instance, in August 2022, Abbott partnered with WW International, Inc. (WeightWatchers). Through this partnership, both companies will combine the weight management program of WeightWatchers for people with diabetes with Abbott's line of FreeStyle Libre products to produce a seamless mobile experience. It will offer knowledge & insights on how to improve their diet, lower the blood sugar levels of patients, and ultimately, help consumers take back control of their health.

GCC And UAE Diabetes Devices Market Report Highlights

  • The pharmaceutical, drugs, and supplies segment led the market and accounted for the largest market share of 39.5% in 2024.
  • The hospital pharmacies segment held the dominant position in the market with the highest revenue share of 55.3% in 2024.
  • The hospital segment dominated the GCC and UAE diabetes devices industry and accounted for the largest revenue share of 42.4% in 2024.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Services
1.2.2. Distribution Channel
1.2.3. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. GCC and UAE Diabetes Devices Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. GCC and UAE Diabetes Devices Market: Services Business Analysis
4.1. Services Market Share, 2024 & 2030
4.2. Services Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Services, 2018 to 2030 (USD Million)
4.4. Devices and Wearables
4.4.1. Devices and Wearables Market, 2018 - 2030 (USD Million)
4.5. Pharma, Drugs and Supplies
4.5.1. Pharma, Drugs and Supplies Market, 2018 - 2030 (USD Million)
4.6. Technology Platforms and Products
4.6.1. Technology Platforms and Products Market, 2018 - 2030 (USD Million)
4.7. Genomics and Multi Omics
4.7.1. Genomics and Multi Omics Market, 2018 - 2030 (USD Million)
4.8. Diabetes Prevention
4.8.1. Diabetes Prevention Market, 2018 - 2030 (USD Million)
4.8.2. Prediabetes Early Intervention
4.8.2.1. Prediabetes Early Intervention Market, 2018 - 2030 (USD Million)
4.8.3. Early Diagnosis and Diabetes
4.8.3.1. Early Diagnosis and Diabetes Market, 2018 - 2030 (USD Million)
4.8.4. Behavioral and Lifestyle Changes
4.8.4.1. Behavioral and Lifestyle Changes Market, 2018 - 2030 (USD Million)
4.9. Diabetes Researches
4.9.1. Diabetes Researches Market, 2018 - 2030 (USD Million)
4.10. Primary Care
4.10.1. Primary Care Market, 2018 - 2030 (USD Million)
Chapter 5. GCC and UAE Diabetes Devices Market: Distribution Channel Business Analysis
5.1. Distribution Channel Market Share, 2024 & 2030
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
5.4. Hospital Pharmacies
5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
5.5. Retail Pharmacies
5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
5.6. Diabetes Clinics/ Centers
5.6.1. Diabetes Clinics/ Centers Market, 2018 - 2030 (USD Million)
5.7. Online Pharmacies
5.7.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
5.8. Others
5.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. GCC and UAE Diabetes Devices Market: End Use Business Analysis
6.1. End Use Market Share, 2024 & 2030
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
6.4.1. Hospitals Market, 2018 - 2030 (USD Million)
6.5. Homecare
6.5.1. Homecare Market, 2018 - 2030 (USD Million)
6.6. Diagnostic Centers
6.6.1. Diagnostic Centers Market, 2018 - 2030 (USD Million)
Chapter 7. GCC and UAE Diabetes Devices Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. Saudi Arabia
7.4.1. Key Country Dynamics
7.4.2. Regulatory Framework
7.4.3. Competitive Insights
7.4.4. Saudi Arabia GCC and UAE Diabetes Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. UAE
7.5.1. Key Country Dynamics
7.5.2. Regulatory Framework
7.5.3. Competitive Insights
7.5.4. UAE GCC and UAE Diabetes Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Oman
7.6.1. Key Country Dynamics
7.6.2. Regulatory Framework
7.6.3. Competitive Insights
7.6.4. Oman GCC and UAE Diabetes Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Qatar
7.7.1. Key Country Dynamics
7.7.2. Regulatory Framework
7.7.3. Competitive Insights
7.7.4. Qatar GCC and UAE Diabetes Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. Kuwait
7.8.1. Key Country Dynamics
7.8.2. Regulatory Framework
7.8.3. Competitive Insights
7.8.4. Kuwait GCC and UAE Diabetes Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.9. Bahrain
7.9.1. Key Country Dynamics
7.9.2. Regulatory Framework
7.9.3. Competitive Insights
7.9.4. Bahrain GCC and UAE Diabetes Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Medtronic
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Abbot Laboratories
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Ascensia Diabetes Care Holdings
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Dexcom
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. F. Hoffmann- La Roche AG
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Sanofi
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Novo Nordisk A/S
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Insulet Corporation
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Ypsomed AG
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Eli Lily
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. Astra Zeneca
8.5.11.1. Overview
8.5.11.2. Financial Performance
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings